Αποτελέσματα Αναζήτησης
1 Ιαν 2021 · Acetylcholinesterase inhibitors (AChEIs, i.e., donepezil, rivastigmine, galantamine), as well as the N-methyl-d-aspartate receptor (NDMAR) antagonist, memantine show moderate potential in improving measurements of cognition, behavior, and activities of daily living in patients with moderate to severe Alzheimer's disease. Overall, the AChEIs and ...
22 Μαρ 2023 · Recently, preclinical studies demonstrated a protective effect of levetiracetam on cognitive function. In the transgenic mice models of Alzheimer's disease, a low dose of levetiracetam could alleviate cognitive decline, through suppression of proinflammatory cytokines expression and inhibition of abnormal tau hyperphosphorylation (36, 37).
22 Οκτ 2022 · In this review, we present an update on the clinical and physiological phase of the AD spectrum, modifiable and non-modifiable risk factors for AD treatment with a focus on prevention strategies, then research models used in AD, followed by a discussion of treatment limitations.
16 Ιουλ 2021 · Background. Many patients with Alzheimer’s disease (AD) are physically frail or have substantial functional impairments. There is growing evidence that such patients are at higher risk for medication-induced adverse events. Furthermore, frailty seems to be more predictive of poor clinical outcomes than chronological age alone.
Side effects are common for people taking medications for dementia symptoms. For most people, these get better after a few weeks of taking the medication. However, not everyone has the same side effects, or has them for the same length of time.
The researchers looked at the effects of each medication separately. They found that those who were taking galantamine had a lower risk of developing severe dementia. This difference did not occur for the other 2 medications they studied (rivastigmine and donepezil).
27 Απρ 2021 · The Effects of Long-term Medication Use in Alzheimer Disease. Neurology. 2021 Apr 27;96 (17):e2247-e2250. doi: 10.1212/WNL.0000000000011843.
